1. Albers GW, Caplan LR, Easton JD, et al. Transient ischemic attack: proposal for a new definition. N Engl J Med 2002;347:1713–1716.
2. Johnston SC, Gress DR, Browner WS, et al. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000;284:2901–2906.
3. Lovett JK, Dennis MS, Sandercock PA, et al. Very early risk of stroke after a first transient ischemic attack. Stroke 2003;34:e138–e140.
5. Levy DE. How transient are transient ischemic attacks? Neurology 1988;38:674–677.
6. Johnston DC, Hill MD. The patient with transient cerebral ischemia: a golden opportunity for stroke prevention. CMAJ 2004;170:1134–1137.
7. Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002;33:901–906.
8. Kaplan RC, Tirschwell DL, Longstreth WT Jr, et al. Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. Neurology 2005;65:835–842.
9. Brown DL, Lisabeth LD, Roychoudhury C, et al. Recurrent stroke risk is higher than cardiac event risk after initial stroke/transient ischemic attack. Stroke 2005;36:1285–1287.
10. Adams HP Jr, Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association.Stroke 2003;34:1056–1083.
11. Adams H, Adams R, del Zoppo GJ, et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the stroke council of the American Heart Association/American Stroke Association. Stroke 2005;36:916–923.
12. Weinberger J, Tegeler JH, McKinney WM, et al. Ultrasonography for diagnosis and management of carotid artery atherosclerosis. J Neuroimaging 1995;5:237–243.
13. Weinberger J, Azhar S, Danisi F, et al. A new non-invasive technique for imaging atherosclerotic plaque in the aortic arch of stroke patients by transcutaneous real-time B-mode ultrasonography: an initial report. Stroke 1998;29:673–676.
14. Horowitz DR, Tuhrim S, Weinberger J, et al. Transesophageal echocardiography: diagnostic and clinical applications in the evaluation of the stroke patient. J Cerebrovasc Dis 1997;6:332–336.
15. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis: North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998;339:1415–1425.
16. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:577–617.
17. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:483S–512S
18. Johnston SC, Nguyen-Huynh MN, Schwartz ME, et al. National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol 2006;60:301–313.
19. Taylor DW, Barnett HJM, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. Lancet 1999;353:2179–2184.
20. Chaturvedi S, Yadav JS. The role of antiplatelet therapy in carotid stenting for ischemic stroke prevention. Stroke 2006;37:1572–1577.
21. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305–1316.
22. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255–1262.
23. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444–1451.
24. Wolf PA, Clagett GP, Easton JD, et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 1999;30:1991–1994.
25. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–2997.
26. Furberg CD, Psaty BM, Pahor M, et al. Clinical implications of recent findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and other studies of hypertension. Ann Intern Med 2001;135:1074–1078.
27. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double-blind randomised trial. BMJ 2002;324:699–702.
28. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003.
29. PROGRESS Colaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033–1041.
30. Diener HC, Sacco R, Yusuf S. Steering Committee; PRoFESS Study Group: Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007;23:368–380.
31. Adams RJ, Chimowitz MI, Alpert JS, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation 2003;108:1278–1290.
32. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke: the Dutch TIA Trial Study Group. N Engl J Med 1991;325:1261–1266.
33. Farrell B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044–1054.
34. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events: the SALT Collaborative Group. Lancet 1991;338:1345–1349.
35. Dalen JE. Aspirin to prevent heart attack and stroke: what's the right dose? Am J Med 2006;119:198–202.
36. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215–1220.
37. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989;321:501–507.
38. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003;289:2947–2957.
39. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE): CAPRIE Steering Committee. Lancet 1996;348:1329–1339.
40. ESPS Group: European Stroke Prevention Study. Stroke 1990;21:1122–1130.
41. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1–13.
42. Derendorf H, VanderMaelen CP, Brickl R-S, et al. Dipyridamole bioavailability in subjects with reduced gastric acidity. J Clin Pharm 2005;45:845–850.
43. Persantine (dipyridamole USP) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2006.
44. Leonardi-Bee J, Bath PM, Bousser MG, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005;36:162–168.
45. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 2006;367:1665–1673.
46. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.
47. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–337.
48. Hankey GJ, Eikelboom JW. Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks. Neurology 2005;64:1117–1121.
49. Bhatt DL, Fox KAA, Hackett GI, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–1717.